Rahimi G, Tecson KM, Elsaid O, et al. - Researchers compared major adverse renal and/or cardiac events (MARCE) among HFpEF (heart failure with preserved ejection fraction) patients with vs without myocardial ischemia, by performing this post hoc analysis in propensity score matched patients from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Herein, 1,747 ischemic patients and 1,207 propensity matched non-ischemic patients were examined. Adjusted analyses revealed a 20% increased risk of MARCE in correlation with ischemia. Diabetes, dyslipidemia and smoking were identified as other important predictors of MARCE. In the subgroup of ischemic HFpEF patients, there was no significant association between revascularization and MARCE. Future work is needed to create tailored interventions for patients with both HFpEF and ischemic heart disease to alleviate the risk of MARCE.